Compounds and methods of use thereof for treatment of cancer
WO2020086739A1
2-(2-acryloyl-2,6-diazaspiro[3.4]octan-6-yl)-6-(1h-indazol-4-yl)-benzonitrile derivatives and related compounds as inhibitors of g12c mutant kras protein for inhibiting tumor metastasis
WO2020028706A1
Heterocyclic spiro compounds and methods of use thereof for the treatment of cancer
HK1252622A1
Substituted quinazoline compounds and their use as inhibitors of g12c mutant kras, hras and/or nras proteins
CN110869357A
Compounds and methods of use thereof for treating cancer
CN110869358A
Covalent inhibitors of KRAS
WO2018218069A1
Quinazoline derivatives as modulators of mutant kras, hras or nras
EP3573964A1
Benzothiophene and benzothiazole compounds and methods of use thereof
EP3573967A1
Fused hetero-hetero bicyclic compounds and methods of use thereof
CN110382483A
Condensed N- heterocyclic compound and its application method
US2020010454A1
Substituted quinazoline and quinazolinone compounds and methods of use thereof
US2019382377A1
1-(3-(6-(3-hydroxynaphthalen-1-yl)benzofuran-2-yl)azetidin-1 yl)prop-2-en-1-one derivatives and similar compounds as kras g12c modulators for treating cancer
EP3573954A1
Fused bicyclic benzoheteroaromatic compounds and methods of use thereof
CN110312711A
Heterocyclic compound and its application method as RAS inhibitor
CN110036010A
The inhibitor of KRAS G12C mutain
US2018015087A1
Conjugates of cereblon binding compounds and G12C mutant KRAS, HRAS or NRAS protein modulating compounds and methods of use thereof
US2019127336A1
Substituted quinazoline compounds and methods of use
WO2017100546A1
Methods for preparation of quinazoline derivatives
CN108779097A
Include the quinazoline compound and its application method of the 2- substitutions of substituted heterocycle
